Loading...
•
Dec 31, 2023
Conmed Q4 2023 Earnings Report
CONMED delivered record revenue in both the fourth quarter and for the full year.
Key Takeaways
CONMED Corporation reported strong financial results for Q4 2023, achieving record revenue for both the quarter and the full year. The company's balanced growth across various businesses and geographies demonstrates the strength of its portfolio. Looking ahead to 2024, CONMED is focused on delivering innovative technology solutions in General Surgery and Orthopedics.
CONMED achieved record revenue in both the fourth quarter and full year of 2023.
The company saw balanced growth across various businesses and geographies.
CONMED is focused on delivering innovative technology solutions in General Surgery and Orthopedics.
Full-year 2024 reported revenue is expected to be between $1.340 billion and $1.365 billion, representing year-over-year growth of approximately 8% to 10%.
Conmed
Conmed
Conmed Revenue by Segment
Conmed Revenue by Geographic Location
Revenue by Segment
Orthopedic Surgery Revenue
CapyFin.comGeneral Surgery Revenue
CapyFin.comSingle-Use Products Revenue
CapyFin.comCapital Products Revenue
CapyFin.comRevenue by Geographic Location
Domestic Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company expects full-year 2024 reported revenue between $1.340 billion and $1.365 billion. The Company expects full-year 2024 adjusted diluted net earnings per share in the range of $4.30 to $4.40.
Positive Outlook
- Full-year 2024 reported revenue is expected to be between $1.340 billion and $1.365 billion.
- Year-over-year revenue growth of approximately 8% to 10% is expected.
- Full-year 2024 adjusted diluted net earnings per share is expected in the range of $4.30 to $4.40.
- Year-over-year adjusted diluted net earnings per share growth of approximately 25% to 28% is expected.
- The impact of foreign currency exchange rates in 2024 is expected to be immaterial.
Revenue & Expenses
Visualization of income flow from segment revenue to net income